In the wake of Evozyne’s hiring of a seasoned tech-company executive as CEO, the Chicago-based biotech company announced it’s developed an AI model that it hopes will revolutionize development of new therapeutic proteins, significantly accelerating the time it takes to bring drugs treating rare diseases to market.
The Evozyne model, developed in collaboration with Santa Clara, Calif.-based computing company Nvidia, will use data-driven “deep-learning technology” to narrow down possible novel proteins that may successfully fill therapeutic or sustainability roles better than proteins found in nature, said CEO Mike Gamson, who took the helm of the Paragon Biosciences portfolio company Monday. He was previously CEO of legal software tech company Relativity.